Catto - Figure 16
Risk Stratification
FIG. 16: Figure 16 illustrates two of the stratification tables from one of the most informative risk stratifications, by the European Organization for the Research and Treatment of Cancer (EORTC).[18] In the United Kingdom we are organizing a clinical trial, CALIBER, that is randomizing patients with recurrent low-grade disease to standard of care, which is endoscopic resection, or to chemoresection.[19] The trial is using the EORTC risk stratification criteria to aid recruitment, using tumor number, size, and recurrence rate in the short term to stage and grade of carcinoma in situ (CIS).[20] This allows calculation of the risk of recurrence within the bladder of a similar noninvasive tumor or progression to a more advanced, more aggressive disease, as illustrated by the risk scores seen in this Figure.
References
Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49;466−77 https://doi.org/10.1016/j.eururo.2005.12.031
Institute of Cancer Research, United Kingdom. Investigating bladder chemotherapy instead of surgery for low risk bladder cancer (CALIBER). ClinicalTrials.gov Identifier: NCT02070120 https://clinicaltrials.gov/ct2/show/NCT02070120 Accessed July 22, 2017
Lewis R, Maynard L, Catto J, et al; CALIBER Trial Management Group. Recruitment aids for a phase II randomised trial in low risk bladder cancer. Eur J Surg Oncol. 2016;42:S244 https://dx.doi.org/10.1016/j.ejso.2016.07.104
